phosphate nephropathy
Recently Published Documents


TOTAL DOCUMENTS

56
(FIVE YEARS 6)

H-INDEX

12
(FIVE YEARS 1)

2021 ◽  
Vol 75 (5) ◽  
pp. 445-450
Author(s):  
Miroslav Merta

Summary: The treatment of gastrointestinal tract (GIT) diseases may, under specific conditions, be significantly influenced by the kidneys or by kidney disorders. One of the potential scenarios of such interaction is the concurrent involvement of the kidneys and the GIT organs within one disorder, another option being the negative impact of impaired renal function on the prognosis of the GIT disease and, finally, the need for an adequate choice and dose adjustment of renally eliminated medication to avoid nephrotoxicity. Renal impairment may occur as an adverse effect of the treatment of the GIT condition and may limit further therapy. In this context we have recently focused on the following clinical situations: the development of acute kidney injury during treatment with proton pump inhibitors, renal complications of inflammatory bowel disease management and the development of acute phosphate nephropathy due to the use phosphate containing laxatives. An early identification of the mechanisms leading to renal injury can prevent the development of irreversible renal lesions and facilitate an efficient treatment of the GIT. Key words: treatment of gastrointestinal tract disorders – acute kidney injury – proton pump inhibitors – renal complications of inflammatory bowel disease – acute phosphate nephropathy


2021 ◽  
Author(s):  
Minfang Zhang ◽  
Wenyan Zhou ◽  
ShaoJun Liu ◽  
Chuanming Hao

Author(s):  
Nesim Akın ◽  
Kemal Şahin Binel ◽  
Hakan Akdam ◽  
Yavuz Yenicerioglu

Acute Phosphate Nephropathy is a clinical and pathological finding characterized by acute and subsequent chronic renal failure following the use of intestinal cleansers containing sodium phosphate. The pathophysiology of Acute Phosphate Nephropathy occurs due to the increase of sodium and water absorption in the proximal tubules due to hypovolemia, and the accumulation of calcium phosphate load in the distal tubules in the collector and distal canals. Renal biopsy findings include acute and chronic tubular damage with tubular and interstitial calcium phosphate deposits. Prevention of Acute Phosphate Nephropathy can be achieved by hydration before and after the use of calcium phosphate in risky patients, minimizing the sodium phosphate dose, and having 12-hour intervals between sodium phosphate applications. In this article, we aimed to present the patients who used sodium phosphate for colonoscopy and developed Acute Phosphate Nephropathy.


2020 ◽  
Vol 8 (12) ◽  
pp. 2585-2589
Author(s):  
Kristianne Rachel Palanca Medina-Liabres ◽  
Bo Mi Kim ◽  
Sejoong Kim

2019 ◽  
Vol 4 (7) ◽  
pp. 1023-1026 ◽  
Author(s):  
Sadia Jahan ◽  
Tom Lea-Henry ◽  
Michael Brown ◽  
Krishna Karpe

2019 ◽  
Vol 4 (7) ◽  
pp. S395 ◽  
Author(s):  
S. JAHAN ◽  
T. Lea-Henry ◽  
M. Brown ◽  
K. Karpe

2018 ◽  
Vol 48 (9) ◽  
pp. 1141-1144 ◽  
Author(s):  
Matthew R. P. Davies ◽  
David Williams ◽  
Olga D. Niewiadomski

2018 ◽  
Vol 23 (1) ◽  
pp. 144-145
Author(s):  
Wenyan Zhou ◽  
Minfang Zhang ◽  
Zhaohui Ni

Author(s):  
Norbert Lameire

This chapter discusses commonly used drugs that frequently are associated with nephrotoxic acute kidney injury (AKI). These drugs include aminoglycosides; old and new formulations of amphotericin B; a number of drug-related crystal-induced AKI, including acute phosphate nephropathy; and methotrexate nephropathy. This chapter also includes a discussion of tumour lysis syndrome and some reflections on the prevention of AKI in tropical countries.


2018 ◽  
Vol 117 (4) ◽  
pp. 348-349 ◽  
Author(s):  
Hsueh-Hao Chang ◽  
Fan-Chi Chang

Sign in / Sign up

Export Citation Format

Share Document